The Plebiscite World
Covid-19, World

AstraZeneca jab has 76% efficacy against symptomatic Covid-19, study finds

The company is preparing to seek emergency approval for use of the shot in the US.

AstraZeneca says its vaccine has 76% efficacy against symptomatic Covid-19, after the firm updated analysis of the third phase of testing.

The revised number follows figures released on Monday reporting the jab was 79% effective, which US federal health officials expressed concern were based on “outdated information”.

In its statement on Thursday the company said the latest analysis confirms “vaccine efficacy consistent with the pre-specified interim analysis” announced on Monday.

The firm said its vaccine also has 100% efficacy against severe or critical disease and hospitalisation due to coronavirus and is 85% effective against symptomatic Covid-19 in patients aged 65 years and over.

Analysis showed 190 symptomatic cases of the illness from the 32,449 trial participants, with the company saying that 76% efficacy was observed 15 days or more after two doses of its shot were given four weeks apart.

Related posts

US Report Documents Atrocities, Ethnic Cleansing in Tigray, NY Times Says

7 months ago

OPEC projects 6.2mbpd growth in oil demand in 2021

10 months ago

Johnson & Johnson vaccine caused Side Effects in Colorado

6 months ago
Exit mobile version